Studies folate receptor alpha testing in women with ovarian cancer
Checks folate receptor alpha in stored tumor samples from adult women with ovarian cancer.
Plain-language title generated from the registry record
Registry title: Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
Key facts
- Where
- Buenos Aires and Ciudad Autonoma de Buenos Aire, ArgentinaSee the 3 sites
Where in Argentina
- Biomakers /ID# 280318Buenos Aires, ArgentinaTaking people
- Hospital Italiano de Buenos Aires /ID# 280315Buenos Aires, ArgentinaTaking people
- Instituto Alexander Fleming /ID# 281479Ciudad Autonoma de Buenos Aire, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT07539844
- Record updated
- 14 September 2026
- Original description
Epithelial ovarian cancer (OC), including fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm with a 5-year relative survival of approximately 50%. This study will evaluate the concordance in folate receptor alpha (FRa) immunohistochemistry (IHC) in adult female participants with ovarian cancer.Read full original descriptionShow less
A Concordance Study of Folate Receptor Alpha (FRa) Testing in InterCon Countries
Epithelial ovarian cancer (OC), including fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm with a 5-year relative survival of approximately 50%. This study will evaluate the concordance in folate receptor alpha (FRa) immunohistochemistry (IHC) in adult female participants with ovarian cancer.
Archived tissue biopsies will be tested for FRa and data from approximately 1,000 participants will be collected. This is a retrospective study and testing will be performed prospectively on archived samples.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 1 Year.
There is no additional burden for participants in this trial.
Inclusion: Surgical or biopsy samples (Formalin Fixed Paraffin Embedded [FFPE]) with tumoral High Grade Serous Ovarian Cancer (HGSOC) material allowing the sectioning of serial slides for all the analyses; Archival specimens should not be older than 5 years in order to control quality of the samples; Specimens containing a minimum of 100 viable tumor cells.
Exclusion: Surgical or biopsy samples (FFPE) with insufficient quantity or quality (sampled more than 5 years ago and/or with less 100 viable tumor cells per section); Tissue obtained following treatment with Mirvetuximab soravtansine or any other FRa targeted therapy; Tissue obtained through fine needle aspirations or liquid specimens, or ascites.